In compliance with paragraphs 3.63 to 3.74 of the JSE Listings Requirements, the following information is disclosed.
A. VESTING IN SHARE APPRECIATION RIGHTS AND SALE OF ORDINARY SHARES BY DIRECTORS
The following transactions are disclosed in relation to SARS:
| 1. Name of director: |
F Abbott (Financial Director) |
| Nature of transaction: |
The off-market issuance of shares to settle SARS |
| Date of vesting of SARS issued in 2013: |
15 November 2018 |
| Date on which SARS issued in 2013 will lapse: |
15 November 2019 |
| Number of 2013 SARS vested to date: |
52 951 |
| 2013 SARS issue value per share: |
R33.18 |
| 1-day Volume Weighted Average price of shares |
R45.94 |
| Nature of transaction: |
On market sale of shares |
| Number of ordinary shares issued to settle 2013 SARS: |
14 708 |
| Selling price per share: |
R48.12 |
| Day highest sale price: |
R49.48 |
| Day lowest sale price: |
R44.59 |
| Proceeds for total on market sale: |
R707 748 |
| Class of Securities: |
Ordinary Shares |
| Nature and extent of director’s interest: |
Direct beneficial |
| Nature of transaction: |
The off-market issuance of shares to settle SARS |
| Date of vesting of SARS issued in 2014: |
17 November 2019 |
| Date on which SARS issued in 2014 will lapse: |
17 November 2020 |
| Number of 2014 SARS vested to date: |
42 414 |
| 2014 SARS issue value per share: |
R18.41 |
| 1-day Volume Weighted Average price of shares |
R45.94 |
| Nature of transaction: |
On market sale of shares |
| Number of ordinary shares issued to settle 2014 SARS: |
25 417 |
| Selling price per share: |
R48.12 |
| Day highest sale price: |
R49.48 |
| Day lowest sale price: |
R44.59 |
| Proceeds for total on market sale: |
R1 223 066 |
| Class of Securities: |
Ordinary Shares |
| Nature and extent of director’s interest: |
Direct beneficial |
| 2. Name of director: |
HE Mashego (Executive Director) |
| Nature of transaction: |
The off-market issuance of shares to settle SARS |
| Date of vesting of SARS issued in 2013: |
15 November 2018 |
| Date on which SARS issued in 2013 will lapse: |
15 November 2019 |
| Number of 2013 SARS vested to date: |
38 212 |
| 2013 SARS issue value per share: |
R33.18 |
| 1-day Volume Weighted Average price of shares |
R45.94 |
| Nature of transaction: |
On market sale of shares |
| Number of ordinary shares issued to settle 2013 SARS: |
10 614 |
| Selling price per share: |
R48.12 |
| High: |
R49.48 |
| Low: |
R44.59 |
| Proceeds for total on market sale: |
R510 745 |
| Class of Securities: |
Ordinary Shares |
| Nature and extent of director’s interest: |
Direct beneficial |
|
Nature of transaction:
|
The off-market issuance of shares to settle SARS |
| Date of vesting of SARS issued in 2014: |
17 November 2019 |
| Date on which SARS issued in 2014 will lapse: |
17 November 2020 |
| Number of 2014 SARS vested to date: |
30 608 |
| 2014 SARS issue value per share: |
R18.41 |
| 1-day Volume Weighted Average price of shares |
R45.94 |
| Nature of transaction: |
On market sale of shares |
| Number of ordinary shares issued to settle 2014 SARS: |
18 342 |
| Selling price per share: |
R48.12 |
| Day highest sale price: |
R49.48 |
| Day lowest sale price: |
R44.59 |
| Proceeds for total on market sale: |
R882 617 |
| Class of Securities: |
Ordinary Shares |
| Nature and extent of director’s interest. |
Direct beneficial |
| 3. Name of director: |
R Bisschoff (Company Secretary) |
| Nature of transaction: |
The off-market issuance of shares to settle SARS |
| Date of vesting of SARS issued in 2013: |
15 November 2018 |
| Date on which SARS issued in 2013 will lapse: |
15 November 2019 |
| Number of 2013 SARS vested to date: |
17 356 |
| 2013 SARS issue value per share: |
R33.18 |
| 1-day Volume Weighted Average price of shares |
R45.94 |
| Nature of transaction: |
On market sale of shares |
| Number of ordinary shares issued to settle 2014 SARS: |
4 820 |
| Selling price per share: |
R48.12 |
| Day highest sale price: |
R49.48 |
| Day lowest sale price: |
R44.59 |
| Proceeds for total on market sale: |
R231 938 |
| Class of Securities: |
Ordinary Shares |
| Nature and extent of director’s interest. |
Direct beneficial |
| Nature of transaction: |
The off-market issuance of shares to settle SARS |
| Date of vesting of SARS issued in 2014: |
17 November 2019 |
| Date on which SARS issued in 2014 will lapse: |
17 November 2020 |
| Number of 2014 SARS vested to date: |
16 180 |
| 2014 SARS issue value per share: |
R18.41 |
| 1-day Volume Weighted Average price of shares |
R45.94 |
| Nature of transaction: |
On market sale of shares |
| Number of ordinary shares issued to settle 2014 SARS: |
9 696 |
| Selling price per share: |
R48.12 |
| Day highest sale price: |
R49.48 |
| Day lowest sale price: |
R44.59
|
| Proceeds for total on market sale: |
R466 571
|
| Class of Securities: |
Ordinary Shares |
| Nature and extent of director’s interest |
Direct beneficial |
B. DEALINGS IN SECURITIES BY DIRECTORS
| 1. Name of director: |
HE Mashego (Executive Director) |
| Nature of transaction: |
On market sale of ordinary shares |
| Date: |
21 August 2019 |
| Class of securities: |
Ordinary shares |
| Sale price per share: |
R50.42 |
| Ordinary shares sold: |
593 |
| Total value of sale: |
R29 899 |
| Nature and extent of director’s interest: |
Direct beneficial |
| 2. Name of company secretary: |
R Bisschoff (Company Secretary) |
| Nature of transaction: |
On market sale of ordinary shares |
| Date: |
21 August 2019 |
| Class of securities: |
Ordinary shares |
| Sale price per share: |
R47.25 |
| Ordinary shares sold: |
43 000 |
| Total value of sale: |
R2 031 750 |
| Nature and extent of company secretary’s interest: |
Direct beneficial |
Prior clearance was obtained in respect of the above dealings by the directors.
For more details contact:
Lauren Fourie
Investor Relations Manager
+27 (0) 071 607 1498 (mobile)
Johannesburg, South Africa
23 August 2019
Sponsor:
J.P. Morgan Equities South Africa Proprietary Limited
